Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Boehringer Ingelheim
US Army
Express Scripts
Farmers Insurance
QuintilesIMS
Julphar
Deloitte
Argus Health

Generated: December 9, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PROMETHAZINE PLAIN

« Back to Dashboard

Clinical Trials for Promethazine Plain

Trial ID Title Status Sponsor Phase Summary
NCT00270777 Improving Safety of Antivenom in People Bitten by Snakes Completed University of Kelaniya Phase 4 A study to increase the safety of polyvalent antivenom involving 1000 patients in three centres: low dose adrenaline, promethazine, & hydrocortisone (alone and in combination) to prevent acute adverse reactions to antivenom in people bitten by snakes: randomised, double blind, placebo-controlled trial.
NCT00429832 A RCT of Ondansetron and Promethazine in the Treatment of Nausea and Vomiting in the Emergency Department Completed GlaxoSmithKline Phase 4 This was a trial comparing two commonly used medications for nausea and vomiting, ondansetron and promethazine, in the Emergency Department.
NCT00429832 A RCT of Ondansetron and Promethazine in the Treatment of Nausea and Vomiting in the Emergency Department Completed University of New Mexico Phase 4 This was a trial comparing two commonly used medications for nausea and vomiting, ondansetron and promethazine, in the Emergency Department.
NCT00455234 Rapid Tranquillization Trial: TREC-India II Completed Christian Medical College, Vellore, India Phase 3 Three hundred consecutive adult patients presenting to the emergency services of the department of psychiatry and who are diagnosed by the treating doctor to be needing tranquillization to control agitated or aggressive behavior will be randomized to receive either Injection Olanzepine I.M. or Injection Haloperidol 10mg + Injection Promethazine 50 mg in this parallel group, block randomized, centrally-randomzed, allocation-concealed, assessor-blinded pragmatic clinical trial. The main outcome measure that the two treatments would be compared on would be the clinical state of the patient 4 hours after intervention, but the rate of tranquillization, degree of sedation, proportions tranquil and / or asleep at 15, 30, 60 and 240 minutes, need for additional medication, use of physical restraints, doctors called back, numbers absconding and adverse effects at each of these time points would also be compared. Compliance with oral medication and adverse effects at the end of 2 weeks would also be compared.
NCT00541671 Prevention of Narcotic-Induced Nausea Terminated Christiana Care Health Services N/A We are doing this study to find out if extra medicine is needed to avoid the chance of nausea sometimes linked to narcotic pain medicine (for example, morphine, dilaudid, fentanyl). Some doctors always give medicine to prevent the possible side effect of nausea, while others do not. We are looking to see if this extra medicine is helpful in preventing nausea. The goal is to screen all patients with pain and enroll enough subjects to reach our goal of 164 evaluable study participants.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Promethazine Plain

Condition Name

Condition Name for Promethazine Plain
Intervention Trials
Nausea 9
Pain 4
Vomiting 4
Postoperative Nausea and Vomiting 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Promethazine Plain
Intervention Trials
Nausea 15
Vomiting 12
Postoperative Nausea and Vomiting 6
Emergencies 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Promethazine Plain

Trials by Country

Trials by Country for Promethazine Plain
Location Trials
United States 20
Iran, Islamic Republic of 3
Lebanon 2
Israel 2
Canada 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Promethazine Plain
Location Trials
Pennsylvania 5
Texas 4
Illinois 1
California 1
Kentucky 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Promethazine Plain

Clinical Trial Phase

Clinical Trial Phase for Promethazine Plain
Clinical Trial Phase Trials
Phase 4 11
Phase 3 9
Phase 2/Phase 3 1
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Promethazine Plain
Clinical Trial Phase Trials
Completed 20
Recruiting 7
Unknown status 6
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Promethazine Plain

Sponsor Name

Sponsor Name for Promethazine Plain
Sponsor Trials
Charleston Laboratories, Inc 4
Merck Sharp & Dohme Corp. 2
Shahid Beheshti University of Medical Sciences 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Promethazine Plain
Sponsor Trials
Other 39
Industry 11
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Accenture
Cipla
Express Scripts
McKinsey
Teva
Deloitte
Cerilliant
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.